Sort
3,198 grants matching “mrna vaccine”
Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis
$1,474,679Paul Stephen Keim · Northern Arizona University · U19 · FY2024 · AI
RNA TRASFECTED DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY
$1,473,595Duke University · P01 · FY2000 · CA
The longevity and nature of the anti-SARS-CoV-2 cellular and humoral immune responses
$1,454,501Michel C Nussenzweig · Rockefeller University · P01 · FY2022 · AI
Innate inflammatory responses during pulmonary infections
$1,451,320Katrin Mayer-Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
MFB: Massively parallel identification of translation regulatory sequences in human and viral mRNAs
$1,440,000Carson Thoreen · Yale University · · FY2024 · BIO
Immunotherapeutic Approaches for AIDS
$1,436,310George N. Pavlakis · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
A Phase 1/2a, randomized study of a Tfh-targeting genetic vaccine adjuvant designed to induce broad, durable immune responses
$1,435,214Kara W Chew · University Of California Los Angeles · U01 · FY2024 · AI
Understanding the Role of the Host Response in HIVSIV Infection
$1,422,365Genoveffa Franchini · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Vector-Borne Diseases: Biology Of Vector Host Relationship
$1,420,391Jose Ribeiro · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
A Phase 1/2a, randomized study of a Tfh-targeting genetic vaccine adjuvant designed to induce broad, durable immune responses
$1,417,453Kara W Chew · University Of California Los Angeles · U01 · FY2025 · AI
Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis
$1,416,075Paul Stephen Keim · Northern Arizona University · U19 · FY2024 · AI
Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs
$1,415,922Leonidas A Stamatatos · Fred Hutchinson Cancer Center · U19 · FY2025 · AI
CoVPN 3001 A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine SDMC
$1,414,274Peter B. Gilbert · Fred Hutchinson Cancer Research Center · UM1 · FY2020 · AI
Poxvirus Biology
$1,412,229Bernard Moss · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Recombinant Virus Vaccines
$1,412,229Bernard Moss · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Structure-Function Studies of the HIV-1 Envelope Glycoproteins and Development of a VLP-forming mRNA vaccine for HIV-1
$1,410,429Paolo Lusso · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
Center of Research Translation on the Osteoimmunology of Bone Infection (CoRTOBI)
$1,402,705Edward M Schwarz · University Of Rochester · P50 · FY2022 · AR
Antigen Processing And Presentation In The Intestine
$1,401,182Brian Kelsall · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
HIV-1 and host interactions at molecular level
$1,400,080Maureen Goodenow · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Early Life Vaccination to Prevent HIV acquisition during Adolescence
$1,397,532Sallie R. Permar · Weill Medical Coll Of Cornell Univ · P01 · FY2021 · AI
Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs
$1,393,751Leonidas A Stamatatos · Fred Hutchinson Cancer Center · U19 · FY2024 · AI
Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis
$1,390,215Paul Stephen Keim · Northern Arizona University · U19 · FY2023 · AI
Early Life Vaccination to Prevent HIV acquisition during Adolescence
$1,381,667Sallie R. Permar · Weill Medical Coll Of Cornell Univ · P01 · FY2023 · AI
Engineering durable immunity by optimizing HIV vaccine parameters to drive long-lived plasma cell development
$1,379,954Bryan Briney · Scripps Research Institute, The · R01 · FY2025 · AI
Early Life Vaccination to Prevent HIV acquisition during Adolescence
$1,375,878Sallie R. Permar · Weill Medical Coll Of Cornell Univ · P01 · FY2022 · AI